Tivic Health announces 1st subject enrolled in optimization study for ncVNS

Tivic Health (TIVC) Systems announced that the first study subject has been enrolled in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will identify device parameters, including frequency and duration of treatment, that optimally influence autonomic nervous system ANS function. The results will be used to inform clinical indication priority and commercial development. Enrollment is expected to be complete by early December. “The effectiveness of Tivic’s non-invasive cervical vagus stimulation or ncVNS, which influences autonomic function, has already been established, demonstrating large ANS responses impacting cardiovascular and central nervous system activity,” stated Tivic Health Chief Scientific Officer Blake Gurfein. “The data from this study will advance our technology toward potential FDA approval for non-invasive treatment of large market indications, where current treatments are invasive, inadequate, or both.”